195 related articles for article (PubMed ID: 19812732)
1. Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034.
Cheng KC; Korfmacher WA; White RE; Njoroge FG
Perspect Medicin Chem; 2007 Jun; 1():1-9. PubMed ID: 19812732
[TBL] [Abstract][Full Text] [Related]
2. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
Njoroge FG; Chen KX; Shih NY; Piwinski JJ
Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
[TBL] [Abstract][Full Text] [Related]
3. Prediction of oral drug absorption in humans--from cultured cell lines and experimental animals.
Cheng KC; Li C; Uss AS
Expert Opin Drug Metab Toxicol; 2008 May; 4(5):581-90. PubMed ID: 18484916
[TBL] [Abstract][Full Text] [Related]
4. The role of exploratory drug metabolism and pharmacokinetics in new drug research: case study-selection of a thrombin receptor antagonist for development.
Hsieh Y; Cheng KC; Wang Y; Chackalamannil S; Xia Y; Korfmacher WA; White RE
Curr Pharm Des; 2009; 15(19):2262-9. PubMed ID: 19601827
[TBL] [Abstract][Full Text] [Related]
5. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
Tsantrizos YS
Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
[TBL] [Abstract][Full Text] [Related]
6. High-throughput screening approaches for investigating drug metabolism and pharmacokinetics.
Roberts SA
Xenobiotica; 2001; 31(8-9):557-89. PubMed ID: 11569526
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.
Thomson JA; Perni RB
Curr Opin Drug Discov Devel; 2006 Sep; 9(5):606-17. PubMed ID: 17002221
[TBL] [Abstract][Full Text] [Related]
8. Optimizing DMPK Properties: Experiences from a Big Pharma DMPK Department.
Sohlenius-Sternbeck AK; Janson J; Bylund J; Baranczewski P; Breitholtz-Emanuelsson A; Hu Y; Tsoi C; Lindgren A; Gissberg O; Bueters T; Briem S; Juric S; Johansson J; Bergh M; Hoogstraate J
Curr Drug Metab; 2016; 17(3):253-70. PubMed ID: 26651977
[TBL] [Abstract][Full Text] [Related]
9. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.
Lin C; Kwong AD; Perni RB
Infect Disord Drug Targets; 2006 Mar; 6(1):3-16. PubMed ID: 16787300
[TBL] [Abstract][Full Text] [Related]
10. Discovery of SCH 900188: A Potent Hepatitis C Virus NS5B Polymerase Inhibitor Prodrug As a Development Candidate.
Chen KX; Venkatraman S; Anilkumar GN; Zeng Q; Lesburg CA; Vibulbhan B; Velazquez F; Chan TY; Bennet F; Jiang Y; Pinto P; Huang Y; Selyutin O; Agrawal S; Huang HC; Li C; Cheng KC; Shih NY; Kozlowski JA; Rosenblum SB; Njoroge FG
ACS Med Chem Lett; 2014 Mar; 5(3):244-8. PubMed ID: 24900812
[TBL] [Abstract][Full Text] [Related]
11. Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
Tong X; Arasappan A; Bennett F; Chase R; Feld B; Guo Z; Hart A; Madison V; Malcolm B; Pichardo J; Prongay A; Ralston R; Skelton A; Xia E; Zhang R; Njoroge FG
Antimicrob Agents Chemother; 2010 Jun; 54(6):2365-70. PubMed ID: 20308381
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
[TBL] [Abstract][Full Text] [Related]
13. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.
Sarrazin C; Rouzier R; Wagner F; Forestier N; Larrey D; Gupta SK; Hussain M; Shah A; Cutler D; Zhang J; Zeuzem S
Gastroenterology; 2007 Apr; 132(4):1270-8. PubMed ID: 17408662
[TBL] [Abstract][Full Text] [Related]
14. Ten years of dengue drug discovery: progress and prospects.
Lim SP; Wang QY; Noble CG; Chen YL; Dong H; Zou B; Yokokawa F; Nilar S; Smith P; Beer D; Lescar J; Shi PY
Antiviral Res; 2013 Nov; 100(2):500-19. PubMed ID: 24076358
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C protease and polymerase inhibitors in development.
Liu-Young G; Kozal MJ
AIDS Patient Care STDS; 2008 Jun; 22(6):449-57. PubMed ID: 18479202
[TBL] [Abstract][Full Text] [Related]
16. Impact of Drug Metabolism/Pharmacokinetics and their Relevance Upon Salviabased Drug Discovery.
Hao DC; Xiao PG
Curr Drug Metab; 2017; 18(12):1071-1084. PubMed ID: 28558633
[TBL] [Abstract][Full Text] [Related]
17. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.
Lawitz E; Sulkowski M; Jacobson I; Kraft WK; Maliakkal B; Al-Ibrahim M; Gordon SC; Kwo P; Rockstroh JK; Panorchan P; Miller M; Caro L; Barnard R; Hwang PM; Gress J; Quirk E; Mobashery N
Antiviral Res; 2013 Sep; 99(3):214-20. PubMed ID: 23747481
[TBL] [Abstract][Full Text] [Related]
18. Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor.
Rosenquist Å; Samuelsson B; Johansson PO; Cummings MD; Lenz O; Raboisson P; Simmen K; Vendeville S; de Kock H; Nilsson M; Horvath A; Kalmeijer R; de la Rosa G; Beumont-Mauviel M
J Med Chem; 2014 Mar; 57(5):1673-93. PubMed ID: 24446688
[TBL] [Abstract][Full Text] [Related]
19. Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.
Bogen SL; Pan W; Ruan S; Nair LG; Arasappan A; Bennett F; Chen KX; Jao E; Venkatraman S; Vibulbhan B; Liu R; Cheng KC; Guo Z; Tong X; Saksena AK; Girijavallabhan V; Njoroge FG
J Med Chem; 2009 Jun; 52(12):3679-88. PubMed ID: 19456105
[TBL] [Abstract][Full Text] [Related]
20. Anti-hepatitis C virus activity and synergistic effect of Nymphaea alba extracts and bioactive constituents in liver infected cells.
Rehman S; Ashfaq UA; Ijaz B; Riazuddin S
Microb Pathog; 2018 Aug; 121():198-209. PubMed ID: 29775725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
